These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29341446)

  • 41. Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.
    Bagel J; Levi E; Tyring S; Knuckles ML
    J Drugs Dermatol; 2014 Nov; 13(11):1374-9. PubMed ID: 25607705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
    Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
    J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS; Finlay AY; Lewis JJ; Sumner MI
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
    Keegan BR
    J Drugs Dermatol; 2015 Aug; 14(8):835-40. PubMed ID: 26267727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement in signs and symptoms in psoriasis patients with Pycnogenol® supplementation.
    Belcaro G; Luzzi R; Hu S; Cesarone MR; Dugall M; Ippolito E; Corsi M; Caporale S
    Panminerva Med; 2014 Mar; 56(1):41-8. PubMed ID: 24637472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
    Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
    Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study between: Carboxytherapy, platelet-rich plasma, and tripolar radiofrequency, their efficacy and tolerability in striae distensae.
    Ahmed NA; Mostafa OM
    J Cosmet Dermatol; 2019 Jun; 18(3):788-797. PubMed ID: 29921041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
    Cassano N; Miracapillo A; Coviello C; Loconsole F; Bellino M; Vena GA
    Clin Drug Investig; 2006; 26(4):227-33. PubMed ID: 17163256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
    Durakovic C; Ray S; Holick MF
    Br J Dermatol; 2004 Jul; 151(1):190-5. PubMed ID: 15270890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses.
    Aubin F; Vigan M; Puzenat E; Blanc D; Drobacheff C; Deprez P; Humbert P; Laurent R
    Br J Dermatol; 2005 Jan; 152(1):99-103. PubMed ID: 15656808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.